Quantitative imaging of Cu, Fe, Mn and Zn in the L-DOPA-treated unilateral 6-hydroxydopamine Parkinson’s disease mouse model by LA-ICP-MS

Biomedical Spectroscopy and Imaging

Volumn 1, Issue 2, 2012, Pages 125-136

  Sussulini, Alessandra ^a   Matusch, Andreas ^a   Klietz, Martin ^b   Bauer, Andreas ^a,c   Depboylu, Candan ^b   Becker, Johanna Sabine ^a  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Department of Orthopedic Surgery   (Germany)

Author keywords

Copper efflux; LA ICP MS; Metallomics; Mouse brain; Parkinson s disease; Quantitative imaging

Indexed keywords

EID: 85013588989     PISSN: 22128794     EISSN: 22128808     Source Type: Journal    
DOI: 10.3233/BSI-2012-0011     Document Type: Article

References (46)

1. D. Alvarez-Fischer, C. Henze, C. Strenzke, J. Westrich, B. Ferger, G.U. Hoglinger, W.H. Oertel and A. Hartmann, Characterization of the striatal 6-OHDA model of Parkinson’s disease in wild type and a-synuclein-deleted mice, Exp. Neurol. 210 (2008), 182-193.
2. J.S. Becker, Inorganic Mass Spectrometry: Principles and Applications, Wiley, Chichester, 2007.
3. J.S. Becker, Bioimaging of metals in brain tissue frommicrometre to nanometre scale by laser ablation inductively coupled plasma mass spectrometry: state of the art and perspectives, Int. J. Mass Spectr. 289 (2010), 65-75.
4. J.S. Becker, A. Matusch, J.S. Becker, B. Wu, C. Palm, A.J. Becker and D. Salber, Mass Spectrometric Imaging (MSI) of metals using advanced BrainMet techniques for biomedical research, Int. J. Mass Spectr. 307 (2011), 3-15.
5. J.S. Becker, S. Niehren, A.Matusch, B.Wu, H.F. Hsieh, U. Kumtabtim, M. Hamester, A. Plaschke-Schlutter and D. Salber, Scaling down the bioimaging of metals by laser microdissection inductively coupled plasma mass spectrometry (LMDICP-MS), Int. J. Mass Spectr. 294 (2010), 1-6.
6. J.S. Becker, D. Pozebon, V.L. Dressler, R. Lobinski and J.S. Becker, LA-ICP-MS studies of zinc exchange by copper in bovine serum albumin using an isotopic enriched copper tracer, J. Analyt. Atomic Spectr. 23 (2008), 1076-1082.
7. J.S. Becker, M.V. Zoriy, M. Dehnhardt, C. Pickhardt and K. Zilles, Copper, zinc, phosphorus and sulfur distribution in thin section of rat brain tissues measured by laser ablation inductively coupled plasma mass spectrometry: Possibility for small-size tumor analysis, J. Analyt. Atomic Spectr. 20 (2005), 912-917.
8. J.S. Becker, M. Zoriy, A. Matusch, B. Wu, D. Salber and C. Palm, Bioimaging of metals by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS), Mass Spectr. Rev. 29 (2010), 156-175.
9. J.S. Becker, M.V. Zoriy, C. Pickhardt, N. Palomero-Gallagher and K. Zilles, Imaging of copper, zinc and other elements in thin section of human brain samples (hippocampus) by laser ablation inductively coupled plasma mass spectrometry, Analyt. Chem. 77 (2005), 3208-3216.
10. M. Boll, M. Alcazaz-Zubeldia, S. Montes and C. Rios, Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases, Neurochem. Res. 33 (2008), 1717-1723.
11. A. Boulamery, N. Simon, J. Vidal and B. Bruguerolle, Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study, Chronobiol. Int. 27 (2010), 251-264.
12. J. Bove and C. Perier, Neurotoxin-based models of Parkinson’s disease, Neuroscience 211 (2011), 51-76.
13. H. Braak, K. Del Tredici, H. Bratzke, J. Hamm-Clement, D. Sandmann-Keil and U. Rüb, Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages), J. Neurol. 249 (2002), 1-5.
14. Y.Z. Chang, Y. Ke, J.R. Du, G.M. Halpern, K.P. Ho, L. Zhu, X.S. Gu, Y.J. Xu, Q.Wang, L.Z. Li, C.Y.Wang and Z.M. Qian, Increased divalent metal transporter 1 expression might be associated with the neurotoxicity of L-DOPA, Mol. Pharmacol. 69 (2006), 968-974.
15. B.S. Choi and W. Zheng, Copper transport to the brain by the blood-brain barrier and blood-CSF barrier, Brain Res. 1248 (2009), 14-21.
16. J.F. Collingwood, R.K.K. Chong, T. Kasama, L. Cervera-Gontard, R.E. Dunin-Borkowski, G. Perry, M. Posfai, S.L. Siedlak, E.T. Simpson, M.A. Smith and J. Dobson, Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer’s plaque core material, J. Alzheimers Dis. 14 (2008), 235-245.
17. S. Darmopil, V.C. Muneton-Gomez, M.L. de Ceballos, M. Bernson and R. Moratalla, Molecular characterization of the tyrosine hydroxylase immunoreactive neurons that appear in the mouse striatum following 6-OHDA lesion and L-DOPA treatment, Eur. J. Neurosci. 27 (2008), 580-592.
18. D.T. Dexter, F.R. Wells, A.J. Lees, F. Agid, Y. Agid, P. Jenner and C.D. Marsden, Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson’s disease, J. Neurochem. 52 (1989), 1830-1836.
19. A. Ektessabi, S. Yoshida and K. Takada, Distribution of iron in a single neuron of patients with Parkinson’s disease, X-Ray Spectr. 28 (1999), 456-460.
20. V. Francardo, A. Recchia, N. Popovic, D. Andersson, H. Nissbrandt and M.A. Cenci, Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson’s disease, Neurobiol. Dis. 42 (2011), 327-340.
21. S. Hall, J.N. Rutledge and T. Schallert, MRI, brain iron and experimental Parkinson’s disease, J. Neurol. Sci. 113 (1992), 198-208.
22. D.J. Hare, J.L. George, R. Grimm, S. Wilkins, P.A. Adlard, R.A. Cherny, A.I. Bush, D.I. Finkelstein and P. Doble, Threedimensional elemental bio-imaging of Fe, Zn, Cu, Mn and P in a 6-hydroxydopamine lesioned mouse brain, Metallomics 2 (2010), 745-753.
23. D.J. Hare, B. Reedy, R. Grimm, S. Wilkins, I. Volitakis, J. George, R. Cherny, A. Bush, D. Finkelstein and P. Doble, Quantitative elemental bio-imaging of Mn, Fe, Cu and Zn in 6-hydroxydopamine induced Parkinsonism mouse models, Metallomics 1 (2009), 53-58.
24. Y. He, P.S.P. Thong, T. Lee, S.K. Leong, C.Y. Shi, P.T.H. Wong, S.Y. Yuan and F. Watt, Increased iron in the substantia nigra of 6-OHDA induced Parkinsonian rats: a nuclear microscopy study, Brain Res. 735 (1996), 149-153.
25. J. Henning, U. Strauss, A. Wree, J. Gimsa, A. Rolfs, R. Benecke and U. Gimsa, Differential astroglial activation in 6-hydroxydopamine models of Parkinson’s disease, Neurosci. Res. 62 (2008), 246-253.
26. E. Hirsch, A.M. Graybiel and Y.A. Agid, Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease, Nature 334 (1988), 345-348.
27. J.C. Lee, J.E. Kim, E.V. Pletneva, J. Faraone-Mennella, H.B. Gray and J.R. Winkler, Protein folding, misfolding, and disease, in: Neurodegenerative Diseases and Metal Ions, A. Sigel, H. Sigel and R.K.O. Siegel, eds, Wiley, Chichester, 2006, pp. 9-60.
28. G. Lessner, O. Schmitt, S.J. Haas, S. Mikkat, M. Kreutzer, A. Wree and M.O. Glocker, Differential proteome of the striatum from hemiparkinsonian rats displays vivid structural remodeling processes, J. Proteome Res. 9 (2010), 4671-4687.
29. W. Linert, G.N.L. Jameson, R.F. Jameson and K.A. Jellinger, The chemical interplay between catecholamines and metal ions in neurological diseases, in: Neurodegenerative Diseases and Metal Ions, A. Sigel, H. Sigel and R.K.O. Siegel, eds, Wiley, Chichester, 2006, pp. 281-320.
30. L. Marinova-Mutafchieva, M. Sadeghian, L. Broom, J.B. Davis, A.D. Medhurst and D.T. Dexter, Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson’s disease, J. Neurochem. 110 (2009), 966-975.
31. A. Matusch, C. Depboylu, C. Palm, B. Wu, G.U. Hoglinger, M.K. Schafer and J.S. Becker, Cerebral bio-imaging of Cu, Fe, Zn and Mn in the MPTP mouse model of Parkinson’s disease using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS), J. Amer. Soc. Mass Spectr. 21 (2010), 161-171.
32. A. Matusch, L.S. Fenn, C. Depboylu, M. Klietz, S. Strohmer, J.A. McLean and J.S. Becker, Combined elemental and biomolecular mass spectrometry imaging (MSI) for probing the inventory of tissue at a micrometer scale, Analyt. Chem. 84 (2012), 3170-3178.
33. H.S. Pall, D.R. Blake, J.M. Gutteridge, A.C.Williams, J. Lunec, M. Hall and A. Taylor, Raised cerebrospinal-fluid copper concentration in Parkinson’s disease, Lancet 2 (1987), 238-241.
34. G. Paxinos and K. Franklin, The Mouse Brain in Stereotaxic Coordinates, Academic Press, San Diego, CA, 2001.
35. J. Pierson, J.L. Norris, H.R. Aerni, P. Svenningsson, R.M. Caprioli and P.E. Andren, Molecular profiling of experimental Parkinson’s disease: direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry, J. Proteome Res. 3 (2004), 289-295.
36. B. Popescu, M. George, U. Bergmann, A. Garachtchenko, M. Kelly, R.McCrea, K. Lüning, R. Devon, G. George, A. Hanson, S. Harder, L. Chapman, I. Pickering and H. Nichol, Mapping metals in Parkinson’s and normal brain using rapidscanning X-ray fluorescence, Phys. Med. Biol. 54 (2009), 651-663.
37. Roche-Pharma-AG, Madopar, product data sheet (SPC), 2009.
38. J. Salazar, N. Mena, S. Hunot, A. Prigent, D. Alvarez-Fischer, M. Arredondo, C. Duyckaerts, V. Sazdovitch, L. Zhao, L.M. Garrick, M.T. Nunez, M.D. Garrick, R. Raisman-Vozari and E.C. Hirsch, Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson’s disease, Proc. Natl. Acad. Sci. USA 105 (2008), 18578-18583.
39. M.K.H. Schäfer, J.P. Herman and S.J. Watson, In situ hybridization histochemistry, in: Imaging Drug Action in the Brain, D. London, ed., CRC Press, Boca Raton, FL, 1992.
40. A.H.V. Schapira, Mitochondrial pathology in Parkinson’s disease, Mount Sinai J. Med. 78 (2011), 872-881.
41. M. Stoger-Pollach, C.D. Treiber, G.P. Resch, D.A. Keays and I. Ennen, EMCD real space maps of magnetospirillum magnetotacticum, Micron 42 (2011), 456-460.
42. W. Sun, K. Sugiyama, X. Fang, H. Yamaguchi, S. Akamine, Y. Magata and H. Namba, Different striatal D2-like receptor function in an early stage after unilateral striatal lesion and medial forebrain bundle lesion in rats, Brain Res. 1317 (2010), 227-235.
43. T. Tarohda, Y. Ishida, K. Kawai, M. Yamamoto and R. Amano, Regional distributions of manganese, iron, copper, and zinc in the rat brain of 6-hydroxydopamine-induced parkisonian rats, Anal. Bioanal. Chem. 383 (2005), 224-234.
44. M. Tome, E. Moreira, J.M. Perez-Figares and A.J. Jimenez, Presence of D1- and D2-like dopamine receptors in the rat, mouse and bovine multiciliated ependyma, J. Neural Transmis. 114 (2007), 983-994.
45. R.J. Uitti, A.H. Rajput, B. Rozdilsky, M. Bickis, T. Wollin and W.K. Yuen, Regional metal concentrations in Parkinson’s disease, other chronic neurological diseases, and control brains, Canad. J. Neurol. Sci. 16 (1989), 310-314.
46. H. Zukor, W. Song, A. Liberman, J. Mui, H. Vali, C. Fillebeen, K. Pantopoulos, T.D. Wu, J.L. Guerquin-Kern and H.M. Schipper, HO-1-mediated macroautophagy: a mechanism for unregulated iron deposition in aging and degenerating neural tissues, J. Neurochem. 109 (2009), 776-791.